Increased circulatory asymmetric dimethylarginine and multiple organ failure: Bile duct ligation in rat as a model

International Journal of Molecular Sciences

Volumn 15, Issue 3, 2014, Pages 3989-4006

  Sheen, Jiunn Ming ^a   Chen, Yu Chieh ^a   Tain, You Lin ^a,b   Huang, Li Tung ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Asymmetric dimethylarginine; Bile duct ligation; Cholestasis; Multiple organ failure; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINO ACID TRANSPORTER; ARGININE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE DISULFIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; ORNITHINE PHENYLACETATE; PROTEIN ARGININE METHYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; SODIUM; TETRAHYDROBIOPTERIN; N,N-DIMETHYLARGININE;

ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; BLOOD FLOWMETRY; BRAIN DAMAGE; CELL ADHESION; DNA POLYMORPHISM; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; KIDNEY INJURY; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; MULTIPLE ORGAN FAILURE; NONHUMAN; ORGAN BLOOD FLOW; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SCORING SYSTEM; ANALOGS AND DERIVATIVES; ANIMAL; BILE DUCT; BLOOD; DISEASE MODEL; FIBROSIS; LIGATION; LIVER; METABOLISM; PATHOLOGY; RAT; SURGERY;

ANIMALS; ARGININE; BILE DUCTS; DISEASE MODELS, ANIMAL; FIBROSIS; LIGATION; LIVER; LIVER CIRRHOSIS; MULTIPLE ORGAN FAILURE; RATS;

EID: 84896448947     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15033989     Document Type: Article

References (127)

1. Vallance, P.; Leone, A.; Calver, A.; Collier, J.; Moncada, S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 1992, 20, S60-S62.
2. Kurose, I.; Wolf, R.; Grisham, M. B.; Granger, D. N. Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules. Am. J. Physiol. 1995, 268, H2224-H2231.
3. Faraci, F. M.; Brian, J. E., Jr.; Heistad, D. D. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am. J. Physiol. 1995, 269, H1522-H1527.
4. Segarra, G.; Medina, P.; Ballester, R. M.; Lluch, P.; Aldasoro, M.; Vila, J. M.; Lluch, S.; Pelligrino, D. A. Effects of some guanidino compounds on human cerebral arteries. Stroke 1999, 30, 2206-2210.
5. Vida, G.; Sulyok, E.; Ertl, T.; Martens-Lobenhoffer, J.; Bode-Boger, S. M. Plasma asymmetric dimethylarginine concentration during the perinatal period. Neonatology 2007, 92, 8-13.
6. Tsikas, D. A critical review and discussion of analytical methods in the L-arginine/nitric oxide area of basic and clinical research. Anal. Biochem. 2008, 379, 139-163.
7. Lücke, T.; Kanzelmeyer, N.; Kemper, M. J.; Tsikas, D.; Das, A. M. Developmental changes in the L-arginine/nitric oxide pathway from infancy to adulthood: Plasma asymmetric dimethylarginine levels decrease with age. Clin. Chem. Lab. Med. 2007, 45, 1525-1530.
8. Vida, G.; Sulyok, E.; Ertl, T.; Martens-Lobenhoffer, J.; Bode-Böger, S. M. Birth by cesarean section is associated with elevated neonatal plasma levels of dimethylarginines. Pediatr. Int. 2012, 54, 476-479.
9. Bode-Böger, S. M.; Scalera, F.; Ignarro, L. J. The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol. Ther. 2007, 114, 295-306.
10. Bode-Böger, S. M.; Muke, J.; Surdacki, A.; Brabant, G.; Böger, R. H.; Frölich, J. C. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc. Med. 2003, 8, 77-81.
11. Tain, Y. L.; Huang, L. T. Asymmetric dimethylarginine: Clinical applications in pediatric medicine. J. Formos. Med. Assoc. 2011, 110, 70-77.
12. Cooke, J. P. Does ADMA cause endothelial dysfunction? Arterioscler. Thromb. Vasc. Biol. 2000, 20, 2032-2037.
13. Vallance, P.; Leiper, J. Cardiovascular biology of the asymmetric dimethylarginine: Dimethylarginine dimethylaminohydrolase pathway. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1023-1030.
14. Baylis, C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat. Clin. Pract. Nephrol. 2006, 2, 209-220.
15. Cardounel, A. J.; Cui, H.; Samouilov, A.; Johnson, W.; Kearns, P.; Tsai, A. L.; Berka, V.; Zweier, J. L. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J. Biol. Chem. 2007, 282, 879-887.
16. Böger, R. H. Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond. Ann. Med. 2006, 38, 126-136.
17. Cooke, J. P. ADMA: Its role in vascular disease. Vasc. Med. 2005, 10, S11-S17.
18. Laleman, W.; Omasta, A.; van de Casteele, M.; Zeegers, M.; Vander, E., I.; van Landeghem, L.; Severi, T.; van Pelt, J.; Roskams, T.; Fevery, J.; et al. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology 2005, 42, 1382-1390.
19. Wang, D.; Strandgaard, S.; Iversen, J.; Wilcox, C. S. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296, R195-R200.
20. Perticone, F.; Sciacqua, A.; Maio, R.; Perticone, M.; Galiano, L. G.; Bruni, R.; di Cello, S.; Pascale, A.; Talarico, G.; Greco, L.; et al. Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int. J. Cardiol. 2010, 142, 236-241.
21. Najbauer, J.; Johnson, B. A.; Young, A. L.; Aswad, D. W. Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins. J. Biol. Chem. 1993, 268, 10501-10509.
22. Bedford, M. T.; Clarke, S. G. Protein arginine methylation in mammals: Who, what, and why. Mol. Cell 2009, 33, 1-13.
23. Closs, E. I.; Basha, F. Z.; Habermeier, A.; Förstermann, U. Interference of L-arginineanalogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997, 1, 65-73.
24. Strobel, J.; Mieth, M.; Endress, B.; Auge, D.; König, J.; Fromm, M. F.; Maas, R. Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). J. Mol. Cell. Cardiol. 2012, 53, 392-400.
25. Teerlink, T.; Luo, Z.; Palm, F.; Wilcox, C. S. Cellular ADMA: Regulation and action. Pharmacol. Res. 2009, 60, 448-460.
26. Wilcken, D. E.; Sim, A. S.; Wang, J.; Wang, X. L. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Mol. Genet. Metab. 2007, 91, 309-317.
27. Bulau, P.; Zakrzewicz, D.; Kitowska, K.; Leiper, J.; Gunther, A.; Grimminger, F.; Eickelberg, O. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292, L18-L24.
28. Wang, J.; Sim, A. S.; Wang, X. L.; Wilcken, D. E. L-Arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells. Cell. Mol. Life Sci. 2006, 63, 2838-2846.
29. Aldámiz-Echevarría, L.; Andrade, F. Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int. J. Mol. Sci. 2012, 13, 11288-11311.
30. Carnegie, P. R.; Fellows, F. C.; Symington, G. R. Urinary excretion of methylarginine in human disease. Metabolism 1977, 26, 531-537.
31. Nijveldt, R. J.; Teerlink, T.; Siroen, M. P.; van Lambalgen, A. A.; Rauwerda, J. A.; van Leeuwen, P. A. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin. Nutr. 2003, 22, 17-22.
32. Nijveldt, R. J.; Siroen, M. P.; van der Hoven, B.; Teerlink, T.; Prins, H. A.; Girbes, A. R.; van Leeuwen, P. A. High plasma arginine concentrations in critically ill patients suffering from hepatic failure. Eur. J. Clin. Nutr. 2004, 58, 587-593.
33. Teerlink, T. ADMA metabolism and clearance. Vasc. Med. 2005, 10, S73-S81.
34. Nijveldt, R. J.; Teerlink, T.; Siroen, M. P.; van der Hoven, B.; Prins, H. A.; Wiezer, M. J.; Meijer, C.; van der Sijp, J. R.; Cuesta, M. A.; Meijer, S.; et al. Elevation of asymmetric dimethylarginine (ADMA) in patients developing hepatic failure after major hepatectomy. J. Parenter. Enter. Nutr. 2004, 28, 382-387.
35. Mookerjee, R. P.; Dalton, R. N.; Davies, N. A.; Hodges, S. J.; Turner, C.; Williams, R.; Jalan, R. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transplant. 2007, 13, 400-405.
36. Lluch, P.; Torondel, B.; Medina, P.; Segarra, G.; del Olmo, J. A.; Serra, M. A.; Rodrigo, J. M. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J. Hepatol. 2004, 41, 55-59.
37. Davids, M.; Richir, M. C.; Visser, M.; Ellger, B.; van den Berghe, G.; van Leeuwen, P. A.; Teerlink, T. Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness. Metabolism 2012, 61, 482-490.
38. Nijveldt, R. J.; Teerlink, T.; van Leeuwen, P. A. The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin. Nutr. 2003, 22, 99-104.
39. Milstien, S.; Katusic, Z. Oxidation of tetrahydrobiopterin by peroxynitrite: Implications for vascular endothelial function. Biochem. Biophys. Res. Commun. 1999, 263, 681-684.
40. Rochette, L.; Lorin, J.; Zeller, M.; Guilland, J. C.; Lorgis, L.; Cottin, Y.; Vergely, C. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: Possible therapeutic targets? Pharmacol. Ther. 2013, 140, 239-257.
41. Wells, S. M.; Holian, A. Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells. Am. J. Respir. Cell Mol. Biol. 2007, 36, 520-528.
42. Sydow, K.; Münzel, T. ADMA and oxidative stress. Atheroscler. Suppl. 2003, 4, 41-51.
43. Lee, D. Y.; Teyssier, C.; Strahl, B. D.; Stallcup, M. R. Role of protein methylation in regulation of transcription. Endocr. Rev. 2005, 26, 147-170.
44. Cerwinka, W. H.; Cooper, D.; Krieglstein, C. F.; Feelisch, M.; Granger, D. N. Nitric oxide modulates endotoxin-induced platelet-endothelial cell adhesion in intestinal venules. Am. J. Physiol. Heart Circ. Physiol. 2002, 282, H1111-H1117.
45. Jeremy, J. Y.; Rowe, D.; Emsley, A. M.; Newby, A. C. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc. Res. 1999, 43, 580-594.
46. Fursule, R. A.; Patil, S. D. Hepatoprotective and antioxidant activity of Phaseolus trilobus, Ait on bile duct ligation induced liver fibrosis in rats. J. Ethnopharmacol. 2010, 129, 416-419.
47. Canbakan, B.; Akin, H.; Tahan, G.; Tarcin, O.; Eren, F.; Atug, O.; Tahan, V.; Imeryuz, N.; Yapicier, O.; Avsar, E.; et al. The effects of pegylated interferon α 2b on bile-duct ligation induced liver fibrosis in rats. Ann. Hepatol. 2009, 8, 234-240.
48. Coban, S.; Yildiz, F.; Terzi, A.; Al, B.; Aksoy, N.; Bitiren, M.; Celik, H. The effects of Nigella sativa on bile duct ligation induced-liver injury in rats. Cell Biochem. Funct. 2010, 28, 83-88.
49. Tahan, G.; Eren, F.; Tarçin, O.; Akin, H.; Tahan, V.; Şahi{dotless}n, H.; Özdoǧan, O.; İmeryüz, N.; Çeli{dotless}kel, Ç.; Avşar, E.; et al. Effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats. Turk. J. Gastroenterol. 2010, 21, 287-292.
50. Tain, Y. L.; Hsieh, C. S.; Chen, C. C.; Sheen, J. M.; Lee, C. T.; Huang, L. T. Melatonin prevents increased asymmetric dimethylarginine in young rats with bile duct ligation. J. Pineal Res. 2010, 48, 212-221.
51. Marques, T. G.; Chaib, E.; da Fonseca, J. H.; Lourenço, A. C.; Silva, F. D.; Ribeiro, M. A., Jr.; Galvão, F. H.; D'Albuquerque, L. A. Review of experimental models for inducing hepatic cirrhosis by bile duct ligation and carbon tetrachloride injection. Acta Cir. Bras. 2012, 27, 589-594.
52. Ayvaz, S.; Kanter, M.; Aksu, B.; Sahin, S. H.; Uzun, H.; Erboga, M.; Pul, M. The effects of hyperbaric oxygen application against cholestatic oxidative stress and hepatic damage after bile duct ligation in rats. J. Surg. Res. 2013, 183, 146-155.
53. Kim, H. G.; Han, J. M.; Lee, H. W.; Lee, J. S.; Son, S. W.; Choi, M. K.; Lee, D. S.; Wang, J. H.; Son, C. G. CGX, a multiple herbal drug, improves cholestatic liver fibrosis in a bile duct ligation-induced rat model. J. Ethnopharmacol. 2013, 145, 653-662.
54. Kim, T. W.; Lee, H. K.; Song, I. B.; Lim, J. H.; Cho, E. S.; Son, H. Y.; Jung, J. Y.; Yun, H. I. Platycodin D attenuates bile duct ligation-induced hepatic injury and fibrosis in mice. Food Chem. Toxicol. 2013, 51, 364-369.
55. Han, J. M.; Kim, H. G.; Choi, M. K.; Lee, J. S.; Park, H. J.; Wang, J. H.; Lee, J. S.; Son, S. W.; Hwang, S. Y.; Son, C. G. Aqueous extract of Artemisia iwayomogi Kitamura attenuates cholestatic liver fibrosis in a rat model of bile duct ligation. Food Chem. Toxicol. 2012, 50, 3505-3513.
56. Veidal, S. S.; Vassiliadis, E.; Bay-Jensen, A. C.; Tougas, G.; Vainer, B.; Karsdal, M. A. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 2010, 3, 5: 1-5: 12.
57. Sheen, J. M.; Huang, L. T.; Hsieh, C. S.; Chen, C. C.; Wang, J. Y.; Tain, Y. L. Bile duct ligation in developing rats: Temporal progression of liver, kidney, and brain damage. J. Pediatr. Surg. 2010, 45, 1650-1658.
58. Yang, Y. Y.; Lee, T. Y.; Huang, Y. T.; Chan, C. C.; Yeh, Y. C.; Lee, F. Y.; Lee, S. D.; Lin, H. C. Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats. Liver Int. 2012, 32, 48-57.
59. Huang, L. T.; Hung, J. F.; Chen, C. C.; Hsieh, C. S.; Yu, H. R.; Hsu, C. N.; Tain, Y. L. Endotoxemia exacerbates kidney injury and increases asymmetric dimethylarginine in young bile duct-ligated rats. Shock 2012, 37, 441-448.
60. Schwedhelm, E.; Maas, R.; Freese, R.; Jung, D.; Lukacs, Z.; Jambrecina, A.; Spickler, W.; Schulze, F.; Böger, R. H. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: Impact on nitric oxide metabolism. Br. J. Clin. Pharmacol. 2008, 65, 51-59.
61. Ljubuncic, P.; Tanne, Z.; Bomzon, A. Evidence of a systemic phenomenon for oxidative stress in cholestatic liver disease. Gut 2000, 47, 710-716.
62. Assimakopoulos, S. F.; Mavrakis, A. G.; Grintzalis, K.; Papapostolou, I.; Zervoudakis, G.; Konstantinou, D.; Chroni, E.; Vagianos, C. E.; Georgiou, C. Superoxide radical formation in diverse organs of rats with experimentally induced obstructive jaundice. Redox. Rep. 2008, 13, 179-184.
63. Grintzalis, K.; Papapostolou, I.; Assimakopoulos, S. F.; Mavrakis, A.; Faropoulos, K.; Karageorgos, N.; Georgiou, C.; Chroni, E.; Konstantinou, D. Time-related alterations of superoxide radical levels in diverse organs of bile duct-ligated rats. Free Radic. Res. 2009, 43, 803-808.
64. Huang, L. T.; Tiao, M. M.; Tain, Y. L.; Chen, C. C.; Hsieh, C. S. Melatonin ameliorates bile duct ligation-induced systemic oxidative stress and spatial memory deficits in developing rats. Pediatr. Res. 2009, 65, 176-180.
65. Tain, Y. L.; Kao, Y. H.; Hsieh, C. S.; Chen, C. C.; Sheen, J. M.; Lin, I. C.; Huang, L. T. Melatonin blocks oxidative stress-induced increased asymmetric dimethylarginine. Free Radic. Biol. Med. 2010, 49, 1088-1098.
66. Pinzani, M.; Rosselli, M.; Zuckermann, M. Liver cirrhosis. Best Pract. Res. Clin. Gastroenterol. 2011, 25, 281-290.
67. D'Amico, G.; Garcia-Tsao, G.; Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis. A systematic review of 118 studies. J. Hepatol. 2006, 44, 217-231.
68. Iwakiri, Y.; Groszmann, R. J. Vascular endothelial dysfunction in cirrhosis. J. Hepatol. 2007, 46, 927-934.
69. Iwakiri, Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int. 2012, 32, 199-213.
70. Wiest, R. Splanchnic and systemic vasodilation: The experimental models. J. Clin. Gastroenterol. 2007, 41, S272-S287.
71. Sarela, A. I.; Mihaimeed, F. M.; Batten, J. J.; Davidson, B. R.; Mathie, R. T. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut 1999, 44, 749-753.
72. Wei, C. L.; Khoo, H. E.; Lee, K. H.; Hon, W. M. Differential expression and localization of nitric oxide synthases in cirrhotic livers of bile duct-ligated rats. Nitric Oxide 2002, 7, 91-102.
73. Mohammed, N. A.; El-Aleem, S. A.; Appleton, I.; Maklouf, M. M.; Said, M.; McMahon, R. F. Expression of nitric oxide synthase isoforms in human liver cirrhosis. J. Pathol. 2003, 200, 647-655.
74. Serna, E.; Mauricio, M. D.; Lluch, P.; Segarra, G.; Cortina, B.; Lluch, S.; Medina, P. Basal release of nitric oxide in the mesenteric artery in portal hypertension and cirrhosis: Role of dimethylarginine dimethylaminohydrolase. J. Gastroenterol. Hepatol. 2013, 28, 880-886.
75. Tain, Y. L.; Chen, C. C.; Lee, C. T.; Kao, Y. H.; Sheen, J. M.; Yu, H. R.; Huang, L. T. Melatonin regulates L-arginine transport and NADPH oxidase in young rats with bile duct ligation: Role of protein kinase C. Pediatr. Res. 2013, 73, 395-401.
76. Chang, K. A.; Lin, I. C.; Sheen, J. M.; Chen, Y. C.; Chen, C. C.; Tain, Y. L.; Hsieh, C. S.; Huang, L. T. Sex differences of oxidative stress to cholestatic liver and kidney injury in young rats. Pediatr. Neonatol. 2013, 54, 95-101.
77. Vizzutti, F.; Romanelli, R. G.; Arena, U.; Rega, L.; Brogi, M.; Calabresi, C.; Masini, E.; Tarquini, R.; Zipoli, M.; Boddi, V.; et al. ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur. J. Clin. Investig. 2007, 37, 509-515.
78. Sciacqua, A.; Perticone, M.; Miceli, S.; Laino, I.; Tassone, E. J.; Grembiale, R. D.; Andreozzi, F.; Sesti, G.; Perticone, F. Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients. Nutr. Metab. Cardiovasc. Dis. 2011, 21, 485-491.
79. Child, C. G.; Turcotte, J. G. Surgery and Portal Hypertension. In The Liver and Portal Hypertension; Child, C. G., Ed.; Saunders: Philadelphia, PA, USA, 1964; pp. 50-64.
80. Eisinger, K.; Krautbauer, S.; Wiest, R.; Karrasch, T.; Hader, Y.; Scherer, M. N.; Farkas, S.; Aslanidis, C.; Buechler, C. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. Eur. J. Clin. Investig. 2013, 43, 926-932.
81. Malinchoc, M.; Kamath, P. S.; Gordon, F. D.; Peine, C. J.; Rank, J.; ter Borg, P. C. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000, 31, 864-871.
82. Bajaj, J. S.; Ahluwalia, V.; Wade, J. B.; Sanyal, A. J.; White, M. B.; Noble, N. A.; Monteith, P.; Fuchs, M.; Sterling, R. K.; Luketic, V.; et al. Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis. J. Hepatol. 2013, 58, 38-44.
83. Maddrey, W. C.; Boitnott, J. K.; Bedine, M. S.; Weber, F. L., Jr.; Mezey, E.; White, R. I., Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978, 75, 193-199.
84. Mookerjee, R. P.; Malaki, M.; Davies, N. A.; Hodges, S. J.; Dalton, R. N.; Turner, C.; Sen, S.; Williams, R.; Leiper, J.; Vallance, P.; et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007, 45, 62-71.
85. Siroen, M. P.; Wiest, R.; Richir, M. C.; Teerlink, T.; Rauwerda, J. A.; Drescher, F. T.; Zorger, N.; van Leeuwen, P. A. Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patients. World J. Gastroenterol. 2008, 14, 7214-7219.
86. Orellana, M.; Rodrigo, R.; Thielemann, L.; Guajardo, V. Bile duct ligation and oxidative stress in the rat: Effects in liver and kidney. Comp. Biochem. Physiol. Toxicol. Pharmacol. 2000, 126, 105-111.
87. Pereira, R. M.; dos Santos, R. A.; Oliveira, E. A.; Leite, V. H.; Dias, F. L.; Rezende, A. S.; Costa, L. P.; Barcelos, L. S.; Teixeira, M. M.; Simoes e Silva, A. C. Development of hepatorenal syndrome in bile duct ligated rats. World J. Gastroenterol. 2008, 14, 4505-4511.
88. Betrosian, A. P.; Agarwal, B.; Douzinas, E. E. Acute renal dysfunction in liver diseases. World J. Gastroenterol. 2007, 13, 5552-5559.
89. Assimakopoulos, S. F.; Vagianos, C. E. Bile duct ligation in rats: A reliable model of hepatorenal syndrome? World J. Gastroenterol. 2009, 15, 121-123.
90. Nijveldt, R. J.; Teerlink, T.; van Guldener, C.; Prins, H. A.; van Lambalgen, A. A.; Stehouwer, C. D.; Rauwerda, J. A.; van Leeuwen, P. A. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol. Dial. Transplant. 2003, 18, 2542-2550.
91. Lluch, P.; Mauricio, M. D.; Vila, J. M.; Segarra, G.; Medina, P.; del Olmo, J. A.; Rodrigo, J. M.; Serra, M. A. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp. Biol. Med. 2006, 231, 70-75.
92. Nicković, V.; Nikolić, J.; Djindjić, N.; Ilić, M.; Nicković, J.; Mladenović, D.; Krstić, N. Diagnostical significance of dimethylarginine in the development of hepatorenal syndrome in patients with alcoholic liver cirrhosis. Vojnosanit. Pregl. 2012, 69, 686-691.
93. Sesti, G.; Mannino, G. C.; de Lorenzo, C.; Greco, A.; Sciacqua, A.; Marini, M. A.; Andreozzi, F.; Perticone, F. A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with chronic kidney disease. Atherosclerosis 2013, 231, 141-144.
94. Andreozzi, F.; Presta, I.; Mannino, G. C.; Scarpelli, D.; di Silvestre, S.; di Pietro, N.; Succurro, E.; Sciacqua, A.; Pandolfi, A.; Consoli, A.; et al. A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity. PLoS One 2012, 7, e36224.
95. Huang, L. T.; Chen, C. C.; Sheen, J. M.; Chen, Y. J.; Hsieh, C. S.; Tain, Y. L. The interaction between high ammonia diet and bile duct ligation in developing rats: Assessment by spatial memory and asymmetric dimethylarginine. Int. J. Dev. Neurosci. 2010, 28, 169-174.
96. Leke, R.; Oliveira, D. L.; Forgiarini, L. F.; Escobar, T. D.; Hammes, T. O.; Meyer, F. S.; Keiding, S.; Silveira, T. R.; Schousboe, A. Impairment of short term memory in rats with hepatic encephalopathy due to bile duct ligation. Metab. Brain Dis. 2013, 28, 187-192.
97. Dhanda, S.; Kaur, S.; Sandhir, R. Preventive effect of N-acetyl-L-cysteine on oxidative stress and cognitive impairment in hepatic encephalopathy following bile duct ligation. Free Radic. Biol. Med. 2013, 56, 204-215.
98. Javadi-Paydar, M.; Ghiassy, B.; Ebadian, S.; Rahimi, N.; Norouzi, A.; Dehpour, A. R. Nitric oxide mediates the beneficial effect of chronic naltrexone on cholestasis-induced memory impairment in male rats. Behav. Pharmacol. 2013, 24, 195-206.
99. Häussinger, D.; Sies, H. Hepatic encephalopathy: Clinical aspects and pathogenetic concept. Arch. Biochem. Biophys. 2013, 536, 97-100.
100. Córdoba, J.; Mínguez, B. Hepatic encephalopathy. Semin. Liver Dis. 2008, 28, 70-80.
101. Montoliu, C.; Rodrigo, R.; Monfor, P.; Llansola, M.; Cauli, O.; Boix, J.; Elmlili, N.; Agusti, A.; Felipo, V. Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications. Metab. Brain Dis. 2010, 25, 39-48.
102. Balasubramaniyan, V.; Wright, G.; Sharma, V.; Davies, N. A.; Sharifi, Y.; Habtesion, A.; Mookerjee, R. P.; Jalan, R. Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302, G145-G152.
103. Corbalán, R.; Montoliu, C.; Miñana, M. D.; del Olmo, J. A.; Serra, M. A.; Aparisi, L.; Rodrigo, J. M.; Felipo, V. Altered modulation of soluble guanylatecyclase by nitric oxide in patients with liver disease. Metab. Brain Dis. 2002, 17, 295-301.
104. Boulton, C. L.; Southam, E.; Garthwaite, J. Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylylcyclase. Neuroscience 1995, 69, 699-703.
105. Hawkins, R. D. NO honey, I don't remember. Neuron 1996, 16, 465-467.
106. Kielstein, J. T.; Donnerstag, F.; Gasper, S.; Menne, J.; Kielstein, A.; Martens-Lobenhoffer, J.; Scalera, F.; Cooke, J. P.; Fliser, D.; Bode-Böger, S. M. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006, 37, 2024-2029.
107. De la Torre, J. C.; Aliev, G. Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: Spatial memory and immunocytochemical changes. J. Cereb. Blood Flow Metab. 2005, 25, 663-672.
108. Notsu, Y.; Nabika, T.; Bokura, H.; Suyama, Y.; Kobayashi, S.; Yamaguchi, S.; Masuda, J. Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage. Am. J. Hypertens. 2009, 22, 257-262.
109. Mallamaci, F.; Tripepi, G.; Cutrupi, S.; Malatino, L. S.; Zoccali, C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int. 2005, 67, 2330-2337.
110. Kielstein, J. T.; Kielstein, A. ADMA and the brain: An unfolding story. Am. J. Hypertens. 2009, doi: 10. 1038/ajh. 2008. 354.
111. Richir, M. C.; van Lambalgen, A. A.; Teerlink, T.; Wisselink, W.; Bloemena, E.; Prins, H. A.; de Vries, T. P.; van Leeuwen, P. A. Low arginine/asymmetric dimethylarginine ratio deteriorates systemic hemodynamics and organ blood flow in a rat model. Crit. Care Med. 2009, 37, 2010-2017.
112. Perticone, F.; Sciacqua, A.; Maio, R.; Perticone, M.; Maas, R.; Boger, R. H.; Tripepi, G.; Sesti, G.; Zoccali, C. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J. Am. Coll. Cardiol. 2005, 46, 518-523.
113. Sciacqua, A.; Grillo, N.; Quero, M.; Sesti, G.; Perticone, F. Asymmetric dimethylarginine plasma levels and endothelial function in newly diagnosed type 2 diabetic patients. Int. J. Mol. Sci. 2012, 13, 13804-13815.
114. Visser, M.; Vermeulen, M. A.; Richir, M. C.; Teerlink, T.; Houdijk, A. P.; Kostense, P. J.; Wisselink, W.; de Mol, B. A.; van Leeuwen, P. A.; Oudemans-van Straaten, H. M. Imbalance of arginine and asymmetric dimethylarginine is associated with markers of circulatory failure, organ failure and mortality in shock patients. Br. J. Nutr. 2012, 107, 1458-1465.
115. Koch, A.; Weiskirchen, R.; Kunze, J.; Dückers, H.; Bruensing, J.; Buendgens, L.; Matthes, M.; Luedde, T.; Trautwein, C.; Tacke, F. Elevated asymmetric dimethylarginine levels predict shortand long-term mortality risk in critically ill patients. J. Crit. Care 2013, 28, 947-953.
116. O'Dwyer, M. J.; Dempsey, F.; Crowley, V.; Kelleher, D. P.; McManus, R.; Ryan, T. Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase-2 gene: A prospective observational study. Crit. Care 2006, 10, R139: 1-R139: 7.
117. Leiper, J.; Murray-Rust, J.; McDonald, N.; Vallance, P. S-Nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc. Natl. Acad. Sci. USA 2002, 99, 13527-13532.
118. Liu, H.; Ma, Z.; Lee, S. S. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000, 118, 937-944.
119. Shafaroodi, H.; Ebrahimi, F.; Moezi, L.; Hashemi, M.; Doostar, Y.; Ghasemi, M.; Dehpour, A. R. Cholestasis induces apoptosis in mice cardiac cells: The possible role of nitric oxide and oxidative stress. Liver Int. 2010, 30, 898-905.
120. Fink, M. P.; Delude, R. L. Epithelial barrier dysfunction: A unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit. Care Clin. 2005, 21, 177-196.
121. Zhang, J. B.; Du, X. G.; Zhang, H.; Li, M. L.; Xiao, G.; Wu, J.; Gan, H. Breakdown of the gut barrier in patients with multiple organ dysfunction syndrome is attenuated by continuous blood purification: Effects on tight junction structural proteins. Int. J. Artif. Organs 2010, 33, 5-14.
122. Assimakopoulos, S. F.; Vagianos, C. E.; Patsoukis, N.; Georgiou, C.; Nikolopoulou, V.; Scopa, C. D. Evidence for intestinal oxidative stress in obstructive jaundice-induced gut barrier dysfunction in rats. Acta Physiol. Scand. 2004, 180, 177-185.
123. Assimakopoulos, S. F.; Scopa, C. D.; Zervoudakis, G.; Mylonas, P. G.; Georgiou, C.; Nikolopoulou, V.; Vagianos, C. E. Bombesin and neurotensin reduce endotoxemia, intestinal oxidative stress, and apoptosis in experimental obstructive jaundice. Ann. Surg. 2005, 241, 159-167.
124. Assimakopoulos, S. F.; Thomopoulos, K. C.; Patsoukis, N.; Georgiou, C. D.; Scopa, C. D.; Nikolopoulou, V. N.; Vagianos, C. E. Evidence for intestinal oxidative stress in patients with obstructive jaundice. Eur. J. Clin. Investig. 2006, 36, 181-187.
125. Assimakopoulos, S. F.; Tsamandas, A. C.; Tsiaoussis, G. I.; Karatza, E.; Zisimopoulos, D.; Maroulis, I.; Kontogeorgou, E.; Georgiou, C. D.; Scopa, C. D.; Thomopoulos, K. C. Intestinal mucosal proliferation, apoptosis and oxidative stress in patients with liver cirrhosis. Ann. Hepatol. 2013, 12, 301-307.
126. Hong, J. Y. F.; Sato, E.; Hiramoto, K.; Nishikawa, M.; Inoue, M. Mechanism of liver injury during obstructive jaundice: Role of nitric oxide, splenic cytokines, and intestinal flora. J. Clin. Biochem. Nutr. 2007, 40, 184-193.
127. Hong, J. Y. F.; Sato, E.; Nishikawa, T.; Hiramoto, K.; Inoue, M. Effect of obstructive jaundice and nitric oxide on the profiles of intestinal bacterial flora in wild and iNOS mice. J. Clin. Biochem. Nutr. 2009, 44, 160-167.